134.55

0.10% -0.14

Pre-market: 134.79 0.24 +0.18%

Apogee Therapeutics Inc (APGE)

Overview News Price History Financials Discussions Forecast

Apogee Therapeutics Inc stock is traded at $134.55, with a volume of 802.16K. It is down -0.10% in the last 24 hours and up +0.67% over the past month. Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Previous Close:

$134.69

Open:

$134.66

24h Volume:

802.16K

Relative Volume:

0.31

Market Cap:

$10.18B

Revenue:

Net Income/Loss:

$-274.62M

P/E Ratio:

-31.09

EPS:

-4.3278

Net Cash Flow:

$-235.37M

1W Performance:

+0.24%

1M Performance:

+0.67%

6M Performance:

+94.13%

1Y Performance:

+266.62%

1-Day Range:

$134.55

$134.70

1-Week Range:

$134.25

$134.88

52-Week Range:

$35.39

$134.88

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc

Sector

Healthcare (1075)

Industry

Biotechnology (600)

Phone

650-394-5230

Address

221 CRESCENT ST., WALTHAM

Employee

261

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

APGE's Discussions on Twitter

Compare APGE vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APGE Apogee Therapeutics Inc	134.55	10.19B	0	-274.62M	-235.37M	-4.3278
VRTX Vertex Pharmaceuticals Inc	525.73	134.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	797.99	82.06B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	876.00	54.10B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.26	44.06B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	359.05	40.64B	5.76B	514.49M	1.10B	4.4813

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Hold
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight
Dec-10-25	Initiated	Deutsche Bank	Buy
Nov-03-25	Initiated	Craig Hallum	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Sep-25-25	Initiated	RBC Capital Mkts	Outperform
Jul-07-25	Reiterated	BTIG Research	Buy
Mar-13-25	Initiated	Citigroup	Buy
Nov-25-24	Initiated	Canaccord Genuity	Buy
May-10-24	Initiated	BofA Securities	Buy
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc Stock (APGE) Latest News

Aug 12, 2026

Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale

Aug 12, 2026

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Aug 12, 2026

Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research - MarketBeat

Aug 12, 2026

APGE Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus

Aug 12, 2026

BTIG Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com

Aug 12, 2026

BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com

Aug 12, 2026

Aug 11, 2026

Apogee Therapeutics Directors Execute Stock Options, Increasing Holdings - Kalkine Media

Aug 11, 2026

Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options - Stock Titan

Aug 11, 2026

Apogee Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com

Aug 11, 2026

Apogee Therapeutics,Q2 2026 Net Loss $85.9 - Moomoo

Aug 11, 2026

My Takeaway On Apogee Therapeutics' Massive Cash Raise Humberto Cruz (GVA0ZiS739) - Mshale

Aug 11, 2026

APGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus

Aug 11, 2026

Aug 10, 2026

Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media

Aug 10, 2026

Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary - TradingView

Aug 10, 2026

Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal - Stock Titan

Aug 10, 2026

Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS - MarketBeat

Aug 10, 2026

Apogee Therapeutics Q2 Loss Widens - marketscreener.com

Aug 10, 2026

Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss - marketscreener.com

Aug 10, 2026

Apogee reports $85.9 million Q2 loss as AbbVie deal advances - Quiver Quantitative

Aug 10, 2026

Apogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingView

Aug 10, 2026

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates - GlobeNewswire

Aug 10, 2026